Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance

Oncogene

Volumn 35, Issue 4, 2016, Pages 468-478

  He, Y ^a   Wu, A C ^a   Harrington, B S ^a   Davies, C M ^a,b   Wallace, S J ^b   Adams, M N ^a   Palmer, J S ^a   Roche, D K ^a   Hollier, B G ^c   Westbrook, T F ^d   Hamidi, H ^e   Konecny, G E ^e   Winterhoff, B ^f   Chetty, N P ^b   Crandon, A J ^b   Oliveira, N B ^b   Shannon, C M ^b   Tinker, A V ^g   Gilks, C B ^h   Coward, J I ^a,b   Lumley, J W ⁱ   Perrin, L C ^b   Armes, J E ^a,b   Hooper, J D ^a   more..

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MAYO CLINIC   (United States)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ WESLEY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CDCP1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; PROTEIN KINASE B; TUMOR PROTEIN;

ADENOCARCINOMA; ANIMAL; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTICELLULAR SPHEROID; NONOBESE DIABETIC MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; ANTIGENS, CD; CARBOPLATIN; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MICE, INBRED NOD; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SPHEROIDS, CELLULAR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955650095     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.101     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Tan DS, Miller RE, Kaye SB. New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer 2013; 108: 1553-1559.
3. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008; 109: 370-376.
4. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-2589.
5. Al-Barrak J, Santos JL, Tinker A, Hoskins P, Gilks CB, Lau H et al. Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. Gynecol Oncol 2011; 122: 107-110.
6. Hoskins PJ, Le N, Gilks B, Tinker A, Santos J, WongF et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. JClinOncol2012; 30: 1656-1662.
7. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010; 177: 1053-1064.
8. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006; 7: 925-934.
9. Wortmann A, He Y, Deryugina EI, Quigley JP, Hooper JD. The cell surface glycoprotein CDCP1 in cancer - insights, opportunities, and challenges. IUBMB Life 2009; 61: 723-730.
10. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res 2013; 73: 1168-1179.
11. Tang T, Li L, Tang J, Li Y, Lin WY, Martin F et al. A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol 2010; 28: 749-755.
12. Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T et al. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol 2008; 134: 1363-1369.
13. Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H et al. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proc Natl Acad Sci USA 2013; 110: 3483-3488.
14. Gao W, Chen L, Ma Z, Du Z, Zhao Z, Hu Z et al. Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. Gastroenterology 2013; 145: 636-46. e5.
15. Ikeda J, Oda T, Inoue M, Uekita T, Sakai R, Okumura M et al. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci 2009; 100: 429-433.
16. Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y et al. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 2010; 70: 5136-5146.
17. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCδ-driven migration. Proc Natl Acad Sci USA 2011; 108: 1931-1936.
18. Casar B, He Y, Iconomou M, Hooper JD, Quigley JP, Deryugina EI. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. Oncogene 2012; 31: 3924-3938.
19. Deryugina EI, Conn EM, Wortmann A, Partridge JJ, Kupriyanova TA, Ardi VC et al. Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Mol Cancer Res 2009; 7: 1197-1211.
20. Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene 2014; 33: 255-268.
21. Liu H, Ong SE, Badu-Nkansah K, Schindler J, White FM, Hynes RO. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci USA 2011; 108: 1379-1384.
22. Huang RY, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr Drug Targets 2012; 13: 1649-1653.
23. Dong Y, He Y, de Boer L, Stack MS, Lumley JW, Clements JA et al. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. J Biol Chem 2012; 287: 9792-9803.
24. Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 2003; 22: 1783-1794.
25. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 2007; 27: 7649-7660.
26. Kemp Z, Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health 2013; 5: 45-51.
27. Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S et al. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002; 93: 723-728.
28. Saga Y, Ohwada M, Suzuki M, Konno R, Kigawa J, Ueno S et al. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncol Rep 2008; 20: 1299-1303.
29. Smith JA, Ngo H, Martin MC, Wolf JK. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol 2005; 98: 141-145.
30. Wortmann A, He Y, Christensen ME, Linn M, Lumley JW, Pollock PM et al. Cellular settings mediating Src substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. J Biol Chem 2011; 286: 42303-42315.
31. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B et al. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res 2009; 15: 2311-2322.
32. Alvares SM, Dunn CA, Brown TA, Wayner EE, Carter WG. The role of membrane microdomains in transmembrane signaling through the epithelial glycoprotein Gp140/CDCP1. Biochim Biophys Acta 2008; 1780: 486-496.
33. McGovern JA, Heinemann JR, Burke LJ, Dawson R, Parker TJ, Upton Z et al. Stratum basale keratinocyte expression of the cell-surface glycoprotein CDCP1 during epidermogenesis and its role in keratinocyte migration. Br J Dermatol 2013; 168: 496-503.
34. Siva AC, Wild MA, Kirkland RE, Nolan MJ, Lin B, Maruyama T et al. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res 2008; 68: 3759-3766.
35. Kollmorgen G, Niederfellner G, Lifke A, Spohn GJ, Rieder N, Vega Harring S et al. Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Mol Oncol 2013; 7: 1142-1151.
36. Adams MN, Harrington BS, He Y, Davies CM, Wallace SJ, Chetty NP et al. EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface. Oncogene 2014; 34: 1375-1383.
37. Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR Jr, Ruff LE et al. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 2001; 159: 2071-2080.
38. Yu X, Liu L, Cai B, He Y, Wan X. Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci 2008; 99: 543-552.
39. Carduner L, Picot CR, Leroy-Dudal J, Blay L, Kellouche S, Carreiras F. Cell cycle arrest or survival signaling through alphav integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. Exp Cell Res 2014; 320: 329-342.